Adult stem cell biotech Mesoblast ($MESO) is in the unusual situation currently of having its stock on hold. This is a relatively rare event and usually portends some kind of major news. The hold is expected to run from June 1 to June 10. Mesoblast will announce ““material corporate developments with respect to certain assets […]
Mesoblast stock on hold: Poll if you expect good or bad news Read More »
One of the rewarding things about being a scientist is the opportunity to connect and even collaborate with other scientists around the world., but at the same time there is nationalism in science too. Some nations, perhaps most of them, and some scientists feel a sense of competition against others at least some of the time.
A role for nationalism in science? Read More »
The biggest debate today in the stem cell world is over how much regulation is needed for new, investigational stem cell therapies that are not as yet approved. Sometimes it feels very lonely being out there publicly advocating for appropriately thorough regulation of stem cell therapies and at times I get a lot of heat for
Alliance for Regenerative Medicine (ARM) Opposes REGROW Act, Risks to Patients Cited Read More »
What’s on your mind on this Monday morning and are you caffeinated enough yet? Depending on where you live it may even be time for dinner, bed, or already early Tuesday. Here are some Monday musings… To get safe and effective stem cell treatments to patients in a responsible, compliant manner you need commercial efforts
Monday morning musings: stocks, ISSCR, grants, CRISPR, New Book Read More »
Stem cell biotech company Bioheart ($BHRT) has had a rough 2015 so far. Could this year be a decisive, negative tipping point for the company? It has a number of clinical trials going, but from my view things seem increasingly uncertain. An oddity amongst stem cell biotechs, Bioheart and its leadership have at times seemed to toy
Bioheart on the edge in 2015? Read More »
Here is a link to the Ocata website, marking the start of a new era for what was formerly Advanced Cell Technology or ACT. It’s been a big summer for stem cell biotech Advanced Cell Technology (ACT; stock ACTCD) as it continues what I would call a process of reinventing itself. What’s been happening? ACT recently
ACT reinventing itself with new name Ocata Therapeutics Read More »
Who might make a fantastic new CIRM President? The California stem cell community is abuzz with this question. This new President will not only lead CIRM today, but also in all likelihood will steer CIRM in its new incarnation after 2017, what I’ve called CIRM 2.0. At least that would be ideal. CIRM has posted a
Dozen Candidates To Be New CIRM President Read More »
It wasn’t so long ago that I did a post explaining why after following the company for years, I finally bought a small amount of stock in the stem cell biotech, Advanced Cell Technology (ACT; symbol ACTC). In part it was motivated by my enthusiasm to see them publishing a paper, a very preliminary paper,
Why Lanza and I sold ACT stock Read More »
I have a new biomedical science column called Lab Dish over at STAT News. Every month or so I will write an opinion piece, often focused on new developments in the field. What’s the focus of Lab Dish? As a cell biology professor, I’ve made a conscious decision to write beyond the usual academic stuff
About Lab Dish, my new column at STAT News Read More »
Ever heard of woolly mice? I hadn’t either until recently. The story begins with de-extinction research. De-extinction can be both cool and arguably a colossal waste of research dollars. The specific effort to de-extinct woolly mammoths fits that dual classification. Woolly mice on the road back to mammoths? Let’s dig into this with some news: